JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $177 to $175.

May 03, 2024 | 6:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Sarepta Therapeutics but lowers the price target from $177 to $175.
The adjustment in price target by JP Morgan reflects a slight change in valuation expectation for Sarepta Therapeutics, likely due to updated analysis or market conditions. However, maintaining the Overweight rating indicates a continued positive outlook on the company's performance. The minor reduction in price target is not expected to have a significant impact on the stock's short-term price movement, as the overall positive stance is maintained.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90